首页 > 最新文献

Journal of Gastric Cancer最新文献

英文 中文
Fatty Acid Binding Protein 5 (FABP5) Promotes Aggressiveness of Gastric Cancer Through Modulation of Tumor Immunity. 脂肪酸结合蛋白5 (FABP5)通过调节肿瘤免疫促进胃癌侵袭性。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-04-01 DOI: 10.5230/jgc.2023.23.e19
Mei-Qing Qiu, Hui-Jun Wang, Ya-Fei Ju, Li Sun, Zhen Liu, Tao Wang, Shi-Feng Kan, Zhen Yang, Ya-Yun Cui, You-Qiang Ke, Hong-Min He, Shu Zhang

Purpose: Gastric cancer (GC) is the second most lethal cancer globally and is associated with poor prognosis. Fatty acid-binding proteins (FABPs) can regulate biological properties of carcinoma cells. FABP5 is overexpressed in many types of cancers; however, the role and mechanisms of action of FABP5 in GC remain unclear. In this study, we aimed to evaluate the clinical and biological functions of FABP5 in GC.

Materials and methods: We assessed FABP5 expression using immunohistochemical analysis in 79 patients with GC and evaluated its biological functions following in vitro and in vivo ectopic expression. FABP5 targets relevant to GC progression were determined using RNA sequencing (RNA-seq).

Results: Elevated FABP5 expression was closely associated with poor outcomes, and ectopic expression of FABP5 promoted proliferation, invasion, migration, and carcinogenicity of GC cells, thus suggesting its potential tumor-promoting role in GC. Additionally, RNA-seq analysis indicated that FABP5 activates immune-related pathways, including cytokine-cytokine receptor interaction pathways, interleukin-17 signaling, and tumor necrosis factor signaling, suggesting an important rationale for the possible development of therapies that combine FABP5-targeted drugs with immunotherapeutics.

Conclusions: These findings highlight the biological mechanisms and clinical implications of FABP5 in GC and suggest its potential as an adverse prognostic factor and/or therapeutic target.

目的:胃癌(GC)是全球第二大致死率最高的癌症,且预后较差。脂肪酸结合蛋白(Fatty acid binding protein, FABPs)能够调控癌细胞的生物学特性。FABP5在许多类型的癌症中过表达;然而,FABP5在胃癌中的作用和作用机制尚不清楚。在本研究中,我们旨在评估FABP5在胃癌中的临床和生物学功能。材料和方法:我们利用免疫组织化学方法对79例胃癌患者FABP5的表达进行了评估,并对其体外和体内异位表达后的生物学功能进行了评估。使用RNA测序(RNA-seq)确定与GC进展相关的FABP5靶点。结果:FABP5表达升高与胃癌预后不良密切相关,其异位表达促进胃癌细胞的增殖、侵袭、迁移和致癌性,提示其在胃癌中可能具有促瘤作用。此外,RNA-seq分析表明,FABP5激活免疫相关途径,包括细胞因子-细胞因子受体相互作用途径、白细胞介素-17信号传导和肿瘤坏死因子信号传导,这为将FABP5靶向药物与免疫疗法联合开发治疗方法提供了重要的理论依据。结论:这些发现突出了FABP5在胃癌中的生物学机制和临床意义,并提示其可能作为不良预后因素和/或治疗靶点。
{"title":"Fatty Acid Binding Protein 5 (FABP5) Promotes Aggressiveness of Gastric Cancer Through Modulation of Tumor Immunity.","authors":"Mei-Qing Qiu,&nbsp;Hui-Jun Wang,&nbsp;Ya-Fei Ju,&nbsp;Li Sun,&nbsp;Zhen Liu,&nbsp;Tao Wang,&nbsp;Shi-Feng Kan,&nbsp;Zhen Yang,&nbsp;Ya-Yun Cui,&nbsp;You-Qiang Ke,&nbsp;Hong-Min He,&nbsp;Shu Zhang","doi":"10.5230/jgc.2023.23.e19","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e19","url":null,"abstract":"<p><strong>Purpose: </strong>Gastric cancer (GC) is the second most lethal cancer globally and is associated with poor prognosis. Fatty acid-binding proteins (FABPs) can regulate biological properties of carcinoma cells. FABP5 is overexpressed in many types of cancers; however, the role and mechanisms of action of FABP5 in GC remain unclear. In this study, we aimed to evaluate the clinical and biological functions of FABP5 in GC.</p><p><strong>Materials and methods: </strong>We assessed FABP5 expression using immunohistochemical analysis in 79 patients with GC and evaluated its biological functions following in vitro and in vivo ectopic expression. FABP5 targets relevant to GC progression were determined using RNA sequencing (RNA-seq).</p><p><strong>Results: </strong>Elevated FABP5 expression was closely associated with poor outcomes, and ectopic expression of FABP5 promoted proliferation, invasion, migration, and carcinogenicity of GC cells, thus suggesting its potential tumor-promoting role in GC. Additionally, RNA-seq analysis indicated that FABP5 activates immune-related pathways, including cytokine-cytokine receptor interaction pathways, interleukin-17 signaling, and tumor necrosis factor signaling, suggesting an important rationale for the possible development of therapies that combine FABP5-targeted drugs with immunotherapeutics.</p><p><strong>Conclusions: </strong>These findings highlight the biological mechanisms and clinical implications of FABP5 in GC and suggest its potential as an adverse prognostic factor and/or therapeutic target.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 2","pages":"340-354"},"PeriodicalIF":2.5,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/13/jgc-23-340.PMC10154133.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9411368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study. 新辅助PD-1抑制剂+阿帕替尼和化疗与阿帕替尼+化疗治疗局部晚期胃癌患者:一项前瞻性队列研究
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-04-01 DOI: 10.5230/jgc.2023.23.e17
Chunjing Wang, Zhen Wang, Yue Zhao, Fujing Wang

Purpose: This study aimed to evaluate the efficacy and safety of neoadjuvant programmed cell death-1 (PD-1) inhibitors plus apatinib and chemotherapy (PAC) in patients with locally advanced gastric cancer (LAGC).

Materials and methods: Seventy-three patients with resectable LAGC were enrolled and named the PAC group (n=39) or apatinib plus chemotherapy (AC) group (n=34) based on the treatment they chose. Neoadjuvant therapy was administered in a 21-day cycle for 3 consecutive cycles, after which surgery was performed.

Results: The PAC group exhibited a higher objective response rate than the AC group (74.4% vs. 58.8%, P=0.159). Moreover, the PAC group showed a numerically better response profile than the AC group (P=0.081). Strikingly, progression-free survival (PFS) (P=0.019) and overall survival (OS) (P=0.049) were prolonged, whereas disease-free survival (DFS) tended to be longer in the PAC group than in the AC group (P=0.056). Briefly, the 3-year PFS, DFS, and OS rates were 76.1%, 76.1%, and 86.7% in the PAC group and 46.9%, 49.9%, and 70.3% in the AC group, respectively. Furthermore, PAC (vs. AC) treatment (hazard ratio=0.286, P=0.034) was independently associated with prolonged PFS in multivariate Cox regression analyses. The incidence of adverse events did not differ between the two groups (all P>0.05), where leukopenia, anemia, hypertension, and other adverse events were commonly observed in the PAC group.

Conclusions: Neoadjuvant PAC therapy may achieve a preferable pathological response, delayed progression, and prolonged survival compared to AC therapy with a similar safety profile in patients with LAGC; however, further validation is warranted.

目的:本研究旨在评价新辅助程序性细胞死亡-1 (PD-1)抑制剂联合阿帕替尼和化疗(PAC)治疗局部晚期胃癌(LAGC)患者的疗效和安全性。材料与方法:入选可切除的LAGC患者73例,根据治疗方案分为PAC组(n=39)和阿帕替尼加化疗(AC)组(n=34)。新辅助治疗以21天为周期,连续3个周期,术后行手术治疗。结果:PAC组客观有效率高于AC组(74.4%比58.8%,P=0.159)。此外,PAC组在数值上优于AC组(P=0.081)。引人注目的是,无进展生存期(PFS) (P=0.019)和总生存期(OS) (P=0.049)延长,而PAC组的无病生存期(DFS)往往长于AC组(P=0.056)。简而言之,PAC组3年PFS、DFS和OS分别为76.1%、76.1%和86.7%,AC组为46.9%、49.9%和70.3%。此外,在多变量Cox回归分析中,PAC (vs. AC)治疗(风险比=0.286,P=0.034)与PFS延长独立相关。两组不良事件发生率无差异(均P>0.05), PAC组常见白细胞减少、贫血、高血压等不良事件。结论:在LAGC患者中,与AC治疗相比,新辅助PAC治疗可能获得更好的病理反应、延迟进展和延长生存期,并且具有相似的安全性;然而,进一步的验证是必要的。
{"title":"Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study.","authors":"Chunjing Wang,&nbsp;Zhen Wang,&nbsp;Yue Zhao,&nbsp;Fujing Wang","doi":"10.5230/jgc.2023.23.e17","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e17","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the efficacy and safety of neoadjuvant programmed cell death-1 (PD-1) inhibitors plus apatinib and chemotherapy (PAC) in patients with locally advanced gastric cancer (LAGC).</p><p><strong>Materials and methods: </strong>Seventy-three patients with resectable LAGC were enrolled and named the PAC group (n=39) or apatinib plus chemotherapy (AC) group (n=34) based on the treatment they chose. Neoadjuvant therapy was administered in a 21-day cycle for 3 consecutive cycles, after which surgery was performed.</p><p><strong>Results: </strong>The PAC group exhibited a higher objective response rate than the AC group (74.4% vs. 58.8%, P=0.159). Moreover, the PAC group showed a numerically better response profile than the AC group (P=0.081). Strikingly, progression-free survival (PFS) (P=0.019) and overall survival (OS) (P=0.049) were prolonged, whereas disease-free survival (DFS) tended to be longer in the PAC group than in the AC group (P=0.056). Briefly, the 3-year PFS, DFS, and OS rates were 76.1%, 76.1%, and 86.7% in the PAC group and 46.9%, 49.9%, and 70.3% in the AC group, respectively. Furthermore, PAC (vs. AC) treatment (hazard ratio=0.286, P=0.034) was independently associated with prolonged PFS in multivariate Cox regression analyses. The incidence of adverse events did not differ between the two groups (all P>0.05), where leukopenia, anemia, hypertension, and other adverse events were commonly observed in the PAC group.</p><p><strong>Conclusions: </strong>Neoadjuvant PAC therapy may achieve a preferable pathological response, delayed progression, and prolonged survival compared to AC therapy with a similar safety profile in patients with LAGC; however, further validation is warranted.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 2","pages":"328-339"},"PeriodicalIF":2.5,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e3/8a/jgc-23-328.PMC10154141.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9415773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Big Step Forward in the New KGCA Guidelines. 新的KGCA指南向前迈进了一大步。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.5230/jgc.2023.23.e8
Sang-Yong Son, Sang-Uk Han
https://jgc-online.org What is learned rapidly becomes outdated. Experiences and things learned by reading research evidence may be selective or inappropriately implemented. In addition, research evidence is everchanging and, consequently, no practitioner can keep abreast of all updates. However, quality and efficiency must be ensured to treat patients encountered in clinical practice. This may be the main reason why so much time is spent developing and reading guidelines.
{"title":"A Big Step Forward in the New KGCA Guidelines.","authors":"Sang-Yong Son,&nbsp;Sang-Uk Han","doi":"10.5230/jgc.2023.23.e8","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e8","url":null,"abstract":"https://jgc-online.org What is learned rapidly becomes outdated. Experiences and things learned by reading research evidence may be selective or inappropriately implemented. In addition, research evidence is everchanging and, consequently, no practitioner can keep abreast of all updates. However, quality and efficiency must be ensured to treat patients encountered in clinical practice. This may be the main reason why so much time is spent developing and reading guidelines.","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"1-2"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f0/4d/jgc-23-1.PMC9911620.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9302263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Sentinel Node Navigation Surgery for Early Gastric Cancer. 前哨淋巴结导航手术治疗早期胃癌的最新进展。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.5230/jgc.2023.23.e4
Eisuke Booka, Hiroya Takeuchi

Maintaining the postoperative quality of life (QOL) while ensuring curability without overtreatment is important in the treatment of early gastric cancer. Postoperative QOL is anticipated to be maintained through minimally invasive function-preserving gastrectomy in early gastric cancer. The concept of the sentinel lymph node (SN) basin is essential to maintain the curability of early gastric cancer using minimally invasive function-preserving gastrectomy. However, additional resection after surgery is difficult to perform in gastric cancer. Thus, the SN basin theory is important. Recently, a multicenter randomized phase III trial in South Korea (SENORITA trial) proved that laparoscopic sentinel node navigation surgery (LSNNS) for stomach preservation results in better postoperative QOL compared with standard gastrectomy in patients with early gastric cancer. LSNNS contributes to patients' QOL based on the concept that curability is not impaired. A multicenter nonrandomized phase III trial is ongoing in Japan, and oncologic safety is expected to be demonstrated. LSNNS has been established as a treatment option for selected patients with early gastric cancer, and its application will become widespread in the future.

维持术后生活质量(QOL)的同时保证不过度治疗的治愈率是早期胃癌治疗的重要内容。早期胃癌微创保功能胃切除术有望维持术后生活质量。前哨淋巴结(SN)盆的概念对于维持早期胃癌微创保功能胃切除术的治愈性至关重要。然而,在胃癌手术后进行额外切除是困难的。因此,SN盆地理论具有重要意义。最近,韩国一项多中心随机III期试验(SENORITA试验)证明,与标准胃切除术相比,腹腔镜前哨淋巴结导航手术(LSNNS)用于胃保存的早期胃癌患者术后生活质量更好。基于治愈率不受损害的概念,LSNNS有助于提高患者的生活质量。一项多中心非随机III期试验正在日本进行,肿瘤安全性有望得到证实。LSNNS已被确定为早期胃癌患者的治疗选择,并将在未来得到广泛应用。
{"title":"Recent Advances in Sentinel Node Navigation Surgery for Early Gastric Cancer.","authors":"Eisuke Booka,&nbsp;Hiroya Takeuchi","doi":"10.5230/jgc.2023.23.e4","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e4","url":null,"abstract":"<p><p>Maintaining the postoperative quality of life (QOL) while ensuring curability without overtreatment is important in the treatment of early gastric cancer. Postoperative QOL is anticipated to be maintained through minimally invasive function-preserving gastrectomy in early gastric cancer. The concept of the sentinel lymph node (SN) basin is essential to maintain the curability of early gastric cancer using minimally invasive function-preserving gastrectomy. However, additional resection after surgery is difficult to perform in gastric cancer. Thus, the SN basin theory is important. Recently, a multicenter randomized phase III trial in South Korea (SENORITA trial) proved that laparoscopic sentinel node navigation surgery (LSNNS) for stomach preservation results in better postoperative QOL compared with standard gastrectomy in patients with early gastric cancer. LSNNS contributes to patients' QOL based on the concept that curability is not impaired. A multicenter nonrandomized phase III trial is ongoing in Japan, and oncologic safety is expected to be demonstrated. LSNNS has been established as a treatment option for selected patients with early gastric cancer, and its application will become widespread in the future.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"159-170"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/96/jgc-23-159.PMC9911613.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9287267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. 韩国 2022 年胃癌实践指南:以证据为基础的多学科方法》(Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach)。
IF 3.2 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.5230/jgc.2023.23.e11
Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung Sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im, Hye Seong Ahn, Hyun Lim, Hyung-Don Kim, Jae-Joon Kim, Jeong Il Yu, Jeong Won Lee, Ji Yeon Park, Jwa Hoon Kim, Kyoung Doo Song, Minkyu Jung, Mi Ran Jung, Sang-Yong Son, Shin-Hoo Park, Soo Jin Kim, Sung Hak Lee, Tae-Yong Kim, Woo Kyun Bae, Woong Sub Koom, Yeseob Jee, Yoo Min Kim, Yoonjin Kwak, Young Suk Park, Hye Sook Han, Su Youn Nam, Seong-Ho Kong

Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this is the 4th gastric cancer guideline published in Korea which is the revised version of previous evidence-based approach in 2018. Current guideline is a collaborative work of the interdisciplinary working group including experts in the field of gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology and guideline development methodology. Total of 33 key questions were updated or proposed after a collaborative review by the working group and 40 statements were developed according to the systematic review using the MEDLINE, Embase, Cochrane Library and KoreaMed database. The level of evidence and the grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation proposition. Evidence level, benefit, harm, and clinical applicability was considered as the significant factors for recommendation. The working group reviewed recommendations and discussed for consensus. In the earlier part, general consideration discusses screening, diagnosis and staging of endoscopy, pathology, radiology, and nuclear medicine. Flowchart is depicted with statements which is supported by meta-analysis and references. Since clinical trial and systematic review was not suitable for postoperative oncologic and nutritional follow-up, working group agreed to conduct a nationwide survey investigating the clinical practice of all tertiary or general hospitals in Korea. The purpose of this survey was to provide baseline information on follow up. Herein we present a multidisciplinary-evidence based gastric cancer guideline.

胃癌是韩国乃至全球最常见的癌症之一。自 2004 年以来,这是韩国发布的第 4 份胃癌指南,也是 2018 年对以往循证方法的修订版。本指南是跨学科工作组的合作成果,包括胃外科、消化内科、内镜、肿瘤内科、腹部放射科、病理科、核医学、放射肿瘤学领域的专家和指南制定方法。经过工作组的合作审查,共更新或提出了 33 个关键问题,并根据使用 MEDLINE、Embase、Cochrane 图书馆和 KoreaMed 数据库进行的系统审查制定了 40 项声明。根据 "建议分级、评估、发展和评价"(Grading of Recommendations, Assessment, Development and Evaluation)命题,对证据水平和建议分级进行了分类。证据水平、益处、危害和临床适用性被视为推荐的重要因素。工作组对建议进行了审查和讨论,以达成共识。在前一部分,总体考虑讨论了内窥镜检查、病理学、放射学和核医学的筛查、诊断和分期。流程图描述了各项陈述,并辅以荟萃分析和参考文献。由于临床试验和系统综述不适合术后肿瘤学和营养学随访,工作组同意在全国范围内对韩国所有三级医院或综合医院的临床实践进行调查。这项调查的目的是提供有关随访的基线信息。在此,我们提出了以证据为基础的多学科胃癌指南。
{"title":"Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach.","authors":"Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung Sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im, Hye Seong Ahn, Hyun Lim, Hyung-Don Kim, Jae-Joon Kim, Jeong Il Yu, Jeong Won Lee, Ji Yeon Park, Jwa Hoon Kim, Kyoung Doo Song, Minkyu Jung, Mi Ran Jung, Sang-Yong Son, Shin-Hoo Park, Soo Jin Kim, Sung Hak Lee, Tae-Yong Kim, Woo Kyun Bae, Woong Sub Koom, Yeseob Jee, Yoo Min Kim, Yoonjin Kwak, Young Suk Park, Hye Sook Han, Su Youn Nam, Seong-Ho Kong","doi":"10.5230/jgc.2023.23.e11","DOIUrl":"10.5230/jgc.2023.23.e11","url":null,"abstract":"<p><p>Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this is the 4th gastric cancer guideline published in Korea which is the revised version of previous evidence-based approach in 2018. Current guideline is a collaborative work of the interdisciplinary working group including experts in the field of gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology and guideline development methodology. Total of 33 key questions were updated or proposed after a collaborative review by the working group and 40 statements were developed according to the systematic review using the MEDLINE, Embase, Cochrane Library and KoreaMed database. The level of evidence and the grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation proposition. Evidence level, benefit, harm, and clinical applicability was considered as the significant factors for recommendation. The working group reviewed recommendations and discussed for consensus. In the earlier part, general consideration discusses screening, diagnosis and staging of endoscopy, pathology, radiology, and nuclear medicine. Flowchart is depicted with statements which is supported by meta-analysis and references. Since clinical trial and systematic review was not suitable for postoperative oncologic and nutritional follow-up, working group agreed to conduct a nationwide survey investigating the clinical practice of all tertiary or general hospitals in Korea. The purpose of this survey was to provide baseline information on follow up. Herein we present a multidisciplinary-evidence based gastric cancer guideline.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"3-106"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/df/jgc-23-3.PMC9911619.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9438183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer. 亚洲局部晚期胃癌患者的新辅助化疗。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.5230/jgc.2023.23.e12
Xie Tong, Peng Zhi, Shen Lin

Presently, surgery is the only treatment approach for gastric cancer and improving the prognosis of locally advanced gastric cancer is one of the key factors in promoting gastric cancer survival benefit. The MAGIC study was the first to demonstrate the efficacy of neoadjuvant chemotherapy (NAC) in European countries. In recent years, several clinical trials have provided evidence for the use of NAC in Asian patients with locally advanced gastric cancer. However, clinical practice guidelines vary between Asian and non-Asian populations. Optimal NAC regimens, proper target populations, and predictors of NAC outcomes in Asian patients are still under investigation. Herein, we summarized the current progress in the administration of NAC in Asian patients with gastric cancer.

手术是目前胃癌唯一的治疗手段,改善局部进展期胃癌的预后是提高胃癌生存效益的关键因素之一。MAGIC研究是欧洲国家首次证明新辅助化疗(NAC)疗效的研究。近年来,一些临床试验为NAC在亚洲局部晚期胃癌患者中的应用提供了证据。然而,临床实践指南在亚洲和非亚洲人群之间有所不同。亚洲患者NAC的最佳方案、适当的目标人群和预后预测因素仍在研究中。在此,我们总结了目前NAC在亚洲胃癌患者中的应用进展。
{"title":"Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer.","authors":"Xie Tong,&nbsp;Peng Zhi,&nbsp;Shen Lin","doi":"10.5230/jgc.2023.23.e12","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e12","url":null,"abstract":"<p><p>Presently, surgery is the only treatment approach for gastric cancer and improving the prognosis of locally advanced gastric cancer is one of the key factors in promoting gastric cancer survival benefit. The MAGIC study was the first to demonstrate the efficacy of neoadjuvant chemotherapy (NAC) in European countries. In recent years, several clinical trials have provided evidence for the use of NAC in Asian patients with locally advanced gastric cancer. However, clinical practice guidelines vary between Asian and non-Asian populations. Optimal NAC regimens, proper target populations, and predictors of NAC outcomes in Asian patients are still under investigation. Herein, we summarized the current progress in the administration of NAC in Asian patients with gastric cancer.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"182-193"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/3b/jgc-23-182.PMC9911622.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Progress in Immunotherapy for Gastric Cancer. 胃癌免疫治疗新进展。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.5230/jgc.2023.23.e10
Jeesun Yoon, Tae-Yong Kim, Do-Youn Oh

Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide. Under the standard of care, patients with advanced GC (AGC) have a median survival time of approximately 12-15 months. With the emergence of immunotherapy as a key therapeutic strategy in medical oncology, relevant changes are expected in the systemic treatment of GC. In the phase III ATTRACTION-2 trial, nivolumab, a monoclonal anti-programmed cell death 1 (PD-1) antibody, as a third- or later-line treatment improved overall survival (OS) compared with placebo in patients with AGC. Furthermore, nivolumab in combination with 5-fluorouracil and platinum as a first-line treatment improved OS in patients with human epidermal growth factor receptor-2 (HER2)-negative AGC in the global phase III CheckMate-649 study. Another anti-PD-1 antibody, pembrolizumab, in combination with trastuzumab and cytotoxic chemotherapy as a first-line treatment, significantly improved the overall response rate in patients with HER2-positive AGC. Therefore, immune checkpoint inhibitors (ICIs) are essential components of the current treatment of GC. Subsequent treatments after ICI combination therapy, such as ICI rechallenge or combination therapy with agents having other modes of action, are being actively investigated to date. On the basis of the success of immunotherapy in the treatment of AGC, various clinical trials are underway to apply this therapeutic strategy in the perioperative and postoperative settings for patients with early GC. This review describes recent progress in immunotherapy and potential immunotherapy biomarkers for GC.

胃癌(GC)是全球癌症相关死亡的第四大原因。在标准治疗下,晚期胃癌(AGC)患者的中位生存时间约为12-15个月。随着免疫治疗作为肿瘤医学的关键治疗策略的出现,胃癌的全身治疗也有望发生相应的变化。在III期ATTRACTION-2试验中,nivolumab(一种单克隆抗程序性细胞死亡1 (PD-1)抗体)作为三线或后期治疗,与安慰剂相比,可改善AGC患者的总生存期(OS)。此外,在全球III期CheckMate-649研究中,nivolumab联合5-氟尿嘧啶和铂作为一线治疗可改善人表皮生长因子受体-2 (HER2)阴性AGC患者的OS。另一种抗pd -1抗体派姆单抗联合曲妥珠单抗和细胞毒性化疗作为一线治疗,显著提高了her2阳性AGC患者的总有效率。因此,免疫检查点抑制剂(ICIs)是当前胃癌治疗的重要组成部分。迄今为止,正在积极研究ICI联合治疗后的后续治疗,例如ICI再挑战或与具有其他作用模式的药物联合治疗。在免疫疗法治疗AGC成功的基础上,各种临床试验正在进行中,以将这种治疗策略应用于早期胃癌患者的围手术期和术后环境。本文综述了GC免疫治疗的最新进展和潜在的免疫治疗生物标志物。
{"title":"Recent Progress in Immunotherapy for Gastric Cancer.","authors":"Jeesun Yoon,&nbsp;Tae-Yong Kim,&nbsp;Do-Youn Oh","doi":"10.5230/jgc.2023.23.e10","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e10","url":null,"abstract":"<p><p>Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide. Under the standard of care, patients with advanced GC (AGC) have a median survival time of approximately 12-15 months. With the emergence of immunotherapy as a key therapeutic strategy in medical oncology, relevant changes are expected in the systemic treatment of GC. In the phase III ATTRACTION-2 trial, nivolumab, a monoclonal anti-programmed cell death 1 (PD-1) antibody, as a third- or later-line treatment improved overall survival (OS) compared with placebo in patients with AGC. Furthermore, nivolumab in combination with 5-fluorouracil and platinum as a first-line treatment improved OS in patients with human epidermal growth factor receptor-2 (HER2)-negative AGC in the global phase III CheckMate-649 study. Another anti-PD-1 antibody, pembrolizumab, in combination with trastuzumab and cytotoxic chemotherapy as a first-line treatment, significantly improved the overall response rate in patients with HER2-positive AGC. Therefore, immune checkpoint inhibitors (ICIs) are essential components of the current treatment of GC. Subsequent treatments after ICI combination therapy, such as ICI rechallenge or combination therapy with agents having other modes of action, are being actively investigated to date. On the basis of the success of immunotherapy in the treatment of AGC, various clinical trials are underway to apply this therapeutic strategy in the perioperative and postoperative settings for patients with early GC. This review describes recent progress in immunotherapy and potential immunotherapy biomarkers for GC.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"207-223"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/68/jgc-23-207.PMC9911614.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Endoscopic Resection of Undifferentiated Early Gastric Cancer. 内镜下未分化早期胃癌切除术。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.5230/jgc.2023.23.e13
Yuichiro Hirai, Seiichiro Abe, Mai Ego Makiguchi, Masau Sekiguchi, Satoru Nonaka, Haruhisa Suzuki, Shigetaka Yoshinaga, Yutaka Saito

Endoscopic resection (ER) is widely performed for early gastric cancer (EGC) with a negligible risk of lymph node metastasis (LNM) in Eastern Asian countries. In particular, endoscopic submucosal dissection (ESD) leads to a high en bloc resection rate, enabling accurate pathological evaluation. As undifferentiated EGC (UD-EGC) is known to result in a higher incidence of LNM and infiltrative growth than differentiated EGC (D-EGC), the indications for ER are limited compared with those for D-EGC. Previously, clinical staging as intramucosal UD-EGC ≤2 cm, without ulceration, was presented as 'weakly recommended' or 'expanded indications' for ER in the guidelines of the United States, Europe, Korea, and Japan. Based on promising long-term outcomes from a prospective multicenter study by the Japan Clinical Oncology Group (JCOG) 1009/1010, the status of this indication has expanded and is now considered 'absolute indications' in the latest Japanese guidelines published in 2021. In this study, which comprised 275 patients with UD-EGC (cT1a, ≤2 cm, without ulceration) treated with ESD, the 5-year overall survival (OS) was 99.3% (95% confidence interval, 97.1%-99.8%), which was higher than the threshold 5-year OS (89.9%). Currently, the levels of evidence grades and recommendations for ER of UD-EGC differ among Japan, Korea, and Western countries. Therefore, a further discussion is warranted to generalize the indications for ER of UD-EGC in countries besides Japan.

在东亚国家,内镜切除(ER)被广泛用于早期胃癌(EGC),其淋巴结转移(LNM)的风险可以忽略不计。特别是内镜下粘膜下剥离术(ESD),整体切除率高,病理评估准确。由于未分化EGC (UD-EGC)比分化EGC (D-EGC)导致更高的LNM发生率和浸润性生长,因此与D-EGC相比,ER的适应症有限。此前,在美国、欧洲、韩国和日本的指南中,临床分期为粘膜内UD-EGC≤2 cm,无溃疡,被列为ER的“弱推荐”或“扩大适应症”。基于日本临床肿瘤小组(JCOG) 1009/1010的前瞻性多中心研究的长期结果,该适应症的地位已经扩大,现在在2021年发布的最新日本指南中被认为是“绝对适应症”。本研究纳入了275例接受ESD治疗的UD-EGC (cT1a,≤2 cm,无溃疡)患者,5年总生存率(OS)为99.3%(95%置信区间,97.1%-99.8%),高于5年OS阈值(89.9%)。目前,日本、韩国和西方国家对UD-EGC ER的证据等级和建议水平存在差异。因此,除日本外,有必要进一步讨论UD-EGC的ER适应症。
{"title":"Endoscopic Resection of Undifferentiated Early Gastric Cancer.","authors":"Yuichiro Hirai,&nbsp;Seiichiro Abe,&nbsp;Mai Ego Makiguchi,&nbsp;Masau Sekiguchi,&nbsp;Satoru Nonaka,&nbsp;Haruhisa Suzuki,&nbsp;Shigetaka Yoshinaga,&nbsp;Yutaka Saito","doi":"10.5230/jgc.2023.23.e13","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e13","url":null,"abstract":"<p><p>Endoscopic resection (ER) is widely performed for early gastric cancer (EGC) with a negligible risk of lymph node metastasis (LNM) in Eastern Asian countries. In particular, endoscopic submucosal dissection (ESD) leads to a high en bloc resection rate, enabling accurate pathological evaluation. As undifferentiated EGC (UD-EGC) is known to result in a higher incidence of LNM and infiltrative growth than differentiated EGC (D-EGC), the indications for ER are limited compared with those for D-EGC. Previously, clinical staging as intramucosal UD-EGC ≤2 cm, without ulceration, was presented as 'weakly recommended' or 'expanded indications' for ER in the guidelines of the United States, Europe, Korea, and Japan. Based on promising long-term outcomes from a prospective multicenter study by the Japan Clinical Oncology Group (JCOG) 1009/1010, the status of this indication has expanded and is now considered 'absolute indications' in the latest Japanese guidelines published in 2021. In this study, which comprised 275 patients with UD-EGC (cT1a, ≤2 cm, without ulceration) treated with ESD, the 5-year overall survival (OS) was 99.3% (95% confidence interval, 97.1%-99.8%), which was higher than the threshold 5-year OS (89.9%). Currently, the levels of evidence grades and recommendations for ER of UD-EGC differ among Japan, Korea, and Western countries. Therefore, a further discussion is warranted to generalize the indications for ER of UD-EGC in countries besides Japan.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"146-158"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/75/jgc-23-146.PMC9911616.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9306304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Role of Adjuvant Radiotherapy in Gastric Cancer. 辅助放疗在胃癌中的作用。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.5230/jgc.2023.23.e1
Jeong Il Yu

Although continuous improvement in the treatment outcome of localized gastric cancer has been achieved through early screening, diagnosis, and treatment and the active application of surgery and adjuvant chemotherapy, the necessity of adjuvant radiotherapy (RT) remains controversial. In this review, based on the results of two recently published randomized phase III studies (Adjuvant Chemoradiation Therapy In Stomach Cancer 2 and ChemoRadiotherapy after Induction chemoTherapy of Cancer in the Stomach) and a meta-analysis of six randomized trials including these two studies, the role of adjuvant RT in gastric cancer was evaluated and discussed, especially in patients who underwent curative gastrectomy with D2 lymphadenectomy. This article also reported the possible indications for adjuvant RT in the current clinical situation and in future research to enable patient-specific treatments according to the risk of recurrence.

虽然通过早期筛查、早期诊断、早期治疗以及手术和辅助化疗的积极应用,局部胃癌的治疗效果不断改善,但是否需要辅助放疗仍存在争议。本综述基于最近发表的两项随机III期研究(胃癌辅助放化疗2和胃癌诱导化疗后放化疗)的结果,以及对包括这两项研究在内的6项随机试验的荟萃分析,评估和讨论了辅助放疗在胃癌中的作用,特别是在行根治性胃切除术合并D2淋巴结切除术的患者中。本文还报道了目前临床情况和未来研究中辅助RT可能的适应症,以便根据复发风险进行个体化治疗。
{"title":"Role of Adjuvant Radiotherapy in Gastric Cancer.","authors":"Jeong Il Yu","doi":"10.5230/jgc.2023.23.e1","DOIUrl":"https://doi.org/10.5230/jgc.2023.23.e1","url":null,"abstract":"<p><p>Although continuous improvement in the treatment outcome of localized gastric cancer has been achieved through early screening, diagnosis, and treatment and the active application of surgery and adjuvant chemotherapy, the necessity of adjuvant radiotherapy (RT) remains controversial. In this review, based on the results of two recently published randomized phase III studies (Adjuvant Chemoradiation Therapy In Stomach Cancer 2 and ChemoRadiotherapy after Induction chemoTherapy of Cancer in the Stomach) and a meta-analysis of six randomized trials including these two studies, the role of adjuvant RT in gastric cancer was evaluated and discussed, especially in patients who underwent curative gastrectomy with D2 lymphadenectomy. This article also reported the possible indications for adjuvant RT in the current clinical situation and in future research to enable patient-specific treatments according to the risk of recurrence.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"194-206"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/58/jgc-23-194.PMC9911621.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Standardized Pathology Report for Gastric Cancer: 2nd Edition. 胃癌标准化病理报告:第 2 版。
IF 3.2 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.5230/jgc.2023.23.e7
Young Soo Park, Myeong-Cherl Kook, Baek-Hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi, Hee Kyung Chang, Soomin Ahn, Mee Soo Chang, Song-Hee Han, Yoonjin Kwak, An Na Seo, Sung Hak Lee, Mee-Yon Cho

The first edition of 'A Standardized Pathology Report for Gastric Cancer' was initiated by the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists and published 17 years ago. Since then, significant advances have been made in the pathologic diagnosis, molecular genetics, and management of gastric cancer (GC). To reflect those changes, a committee for publishing a second edition of the report was formed within the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. This second edition consists of two parts: standard data elements and conditional data elements. The standard data elements contain the basic pathologic findings and items necessary to predict the prognosis of GC patients, and they are adequate for routine surgical pathology service. Other diagnostic and prognostic factors relevant to adjuvant therapy, including molecular biomarkers, are classified as conditional data elements to allow each pathologist to selectively choose items appropriate to the environment in their institution. We trust that the standardized pathology report will be helpful for GC diagnosis and facilitate large-scale multidisciplinary collaborative studies.

第一版《胃癌标准化病理报告》由韩国病理学家协会胃肠道病理研究小组发起,于 17 年前出版。从那时起,胃癌(GC)的病理诊断、分子遗传学和治疗取得了重大进展。为了反映这些变化,韩国病理学家学会胃肠道病理研究组成立了一个委员会,负责出版该报告的第二版。第二版由两部分组成:标准数据元素和条件数据元素。标准数据元素包含基本病理结果和预测 GC 患者预后所需的项目,足以满足常规外科病理服务的需要。与辅助治疗相关的其他诊断和预后因素(包括分子生物标记物)被归类为条件数据元素,以便每位病理学家根据自己所在机构的环境选择合适的项目。我们相信,标准化病理报告将有助于 GC 诊断,并促进大规模多学科合作研究。
{"title":"A Standardized Pathology Report for Gastric Cancer: 2nd Edition.","authors":"Young Soo Park, Myeong-Cherl Kook, Baek-Hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi, Hee Kyung Chang, Soomin Ahn, Mee Soo Chang, Song-Hee Han, Yoonjin Kwak, An Na Seo, Sung Hak Lee, Mee-Yon Cho","doi":"10.5230/jgc.2023.23.e7","DOIUrl":"10.5230/jgc.2023.23.e7","url":null,"abstract":"<p><p>The first edition of 'A Standardized Pathology Report for Gastric Cancer' was initiated by the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists and published 17 years ago. Since then, significant advances have been made in the pathologic diagnosis, molecular genetics, and management of gastric cancer (GC). To reflect those changes, a committee for publishing a second edition of the report was formed within the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. This second edition consists of two parts: standard data elements and conditional data elements. The standard data elements contain the basic pathologic findings and items necessary to predict the prognosis of GC patients, and they are adequate for routine surgical pathology service. Other diagnostic and prognostic factors relevant to adjuvant therapy, including molecular biomarkers, are classified as <i>conditional data elements</i> to allow each pathologist to selectively choose items appropriate to the environment in their institution. We trust that the standardized pathology report will be helpful for GC diagnosis and facilitate large-scale multidisciplinary collaborative studies.</p>","PeriodicalId":56072,"journal":{"name":"Journal of Gastric Cancer","volume":"23 1","pages":"107-145"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/ed/jgc-23-107.PMC9911618.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Gastric Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1